journal article·2015-11

Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination

Nuno A. Fonseca, Ana S. Rodrigues, Paulo Rodrigues-Santos, Vera Alves, Ana C. Gregório, Ângela Valério-Fernandes, Lígia C. Gomes-da-Silva, Manuel Santos Rosa, Vera Moura, João Ramalho-Santos, Sérgio Simões, João Nuno Moreira

Biomaterials· Volume 69
Publisher page

Abstract

Breast cancer stem cells (CSC) are thought responsible for tumor growth and relapse, metastization and active evasion to standard chemotherapy. The recognition that CSC may originate from non-stem cancer cells (non-SCC) through plastic epithelial-to-mesenchymal transition turned these into relevant cell targets. Of crucial importance for successful therapeutic intervention is the identification of surface receptors overexpressed in both CSC and non-SCC. Cell surface nucleolin has been described as overexpressed in cancer cells as well as a tumor angiogenic marker. Herein we have addressed the questions on whether nucleolin was a common receptor among breast CSC and non-SCC and whether it could be exploited for targeting purposes. Liposomes functionalized with the nucleolin-binding F3 peptide, targeted simultaneously, nucleolin-overexpressing putative breast CSC and non-SCC, which was paralleled by OCT4 and NANOG mRNA levels in cells from triple negative breast cancer (TNBC) origin. In murine embryonic stem cells, both nucleolin mRNA levels and F3 peptide-targeted liposomes cellular association were dependent on the stemness status. An in vivo tumorigenic assay suggested that surface nucleolin overexpression per se, could be associated with the identification of highly tumorigenic TNBC cells. This proposed link between nucleolin expression and the stem-like phenotype in TNBC, enabled 100% cell death mediated by F3 peptide-targeted synergistic drug combination, suggesting the potential to abrogate the plasticity and adaptability associated with CSC and non-SCC. Ultimately, nucleolin-specific therapeutic tools capable of simultaneous debulk multiple cellular compartments of the tumor microenvironment may pave the way towards a specific treatment for TNBC patient care.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · RNA modifications and cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (56)

Show source-provided references
1. Hallmarks of cancer: the next generation10.1016/j.cell.2011.02.013 ↗
2. Prospective identification of tumorigenic breast cancer cells10.1073/pnas.0530291100 ↗
3. Cancer stem cells: current status and evolving complexities10.1016/j.stem.2012.05.007 ↗
4. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links10.1016/j.semcancer.2012.04.001 ↗
5. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome10.1016/j.stem.2007.08.014 ↗
6. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis10.1002/stem.563 ↗
7. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways10.1038/nrclinonc.2010.196 ↗
8. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations10.1073/pnas.0810956106 ↗
9. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer10.1158/1535-7163.MCT-12-0466 ↗
10. Breast-cancer stem cells-beyond semantics10.1016/S1470-2045(11)70191-7 ↗
11. Rational design of cancer-drug combinations10.1056/NEJMcibr072593 ↗
12. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo10.1517/17425247.2010.538678 ↗
13. Cancer stem cell niche: the place to be10.1158/0008-5472.CAN-10-3220 ↗
14. Nanoparticle delivery of cancer drugs10.1146/annurev-med-040210-162544 ↗
15. Poised chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity10.1016/j.cell.2013.06.005 ↗
16. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo10.1073/pnas.062189599 ↗
17. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin10.1182/blood-2007-01-064428 ↗
18. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels10.1083/jcb.200304132 ↗
19. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer10.1007/s10549-011-1688-7 ↗
20. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination10.1016/j.jconrel.2014.09.024 ↗
21. Nucleolin maintains embryonic stem cell self-renewal by suppression of p53 protein-dependent pathway10.1074/jbc.M111.225185 ↗
22. Functions of the histone chaperone nucleolin in diseases10.1007/1-4020-5466-1_7 ↗
23. Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells10.1073/pnas.1114438109 ↗
24. Mice cloned from embryonic stem cells10.1073/pnas.96.26.14984 ↗
25. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells10.1016/j.ejpb.2013.04.007 ↗
26. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity10.1023/A:1014434732752 ↗
27. Bridging cancer biology and the patients' needs with nanotechnology-based approaches10.1016/j.ctrv.2014.02.002 ↗
28. Doxil(R)–the first FDA-approved nano-drug: lessons learned10.1016/j.jconrel.2012.03.020 ↗
29. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient10.1016/j.bbamem.2006.05.028 ↗
30. Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles10.1021/la049505j ↗
31. Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers10.1021/la0479105 ↗
32. Physicochemical and biological characterization of ceramide-containing liposomes: paving the way to ceramide therapeutic application10.1021/la800207z ↗
33. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells10.1007/s10549-011-1692-y ↗
34. A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy10.1016/j.bbrc.2012.10.119 ↗
35. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature10.1158/0008-5472.CAN-08-2741 ↗
36. Tumorsphere assay provides more accurate prediction of in vivo responses to chemotherapeutics10.1007/s10529-013-1393-1 ↗
37. Trypan blue exclusion test of cell viability
38. Energy metabolism in human pluripotent stem cells and their differentiated counterparts10.1371/journal.pone.0020914 ↗
39. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays10.1016/j.jim.2009.06.008 ↗
40. Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer10.1002/cyto.a.20634 ↗
41. Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines10.3892/ol.2012.916 ↗
42. Structure and functions of nucleolin10.1242/jcs.112.6.761 ↗
43. Optimizing combination chemotherapy by controlling drug ratios10.1124/mi.7.4.8 ↗
44. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer10.1038/bjc.2011.159 ↗
45. Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform10.2217/nnm.12.174 ↗
46. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype10.1136/jcp.2011.090456 ↗
47. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism10.1158/0008-5472.CAN-10-0920 ↗
48. Tumor-initiating cells are rare in many human tumors10.1016/j.stem.2010.08.009 ↗
49. Efficient tumour formation by single human melanoma cells10.1038/nature07567 ↗
50. Cancer stem cell markers in breast neoplasias: their relevance and distribution in distinct molecular subtypes10.1007/s00428-012-1237-8 ↗
51. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia10.1073/pnas.1018866109 ↗
52. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro10.1016/S0005-2736(03)00108-1 ↗
53. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity10.1016/j.taap.2012.04.008 ↗
54. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer10.1016/j.jconrel.2013.07.014 ↗
55. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors10.1016/j.biomaterials.2013.01.077 ↗
56. CD44 regulates vascular endothelial barrier integrity via a PECAM-1 dependent mechanism10.1007/s10456-013-9346-9 ↗